Cat. # CHI-HF-210BTNL2
|Synonyms||Butyrophilin-like Protein 2; BTN7|
|Source/Host||HEK 293 cells|
The extracellular domain of human BTNL2 (aa 24-455) is fused to the N-terminus of the Fc region of human IgG1.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
|Reconstitution||Reconstitute at 100μg/ml in sterile PBS.|
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Other Product Data|| |
NCBI reference NP_062548.1: BTNL2 (human)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C. |
Working aliquots are stable for up to 3 months when stored at -20°C.
BTNL2 (human):Fc (human) (rec.)
Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology to the B7 costimulatory molecules, polymorphisms of which have been recently associated through genetic analysis; to sporadic inclusion body myositis and sarcoidosis. BTNL2 mRNA is highly expressed in lymphoid tissues as well as in intestine. BTNL2-Ig fusion protein was shown to recognize a putative receptor whose expression on B and T cells was significantly enhanced after activation. It inhibited T cell proliferation and TCR activation of NFAT, NF-κB and AP-1 signaling pathways. BTNL2 is the first member of the butyrophilin family that regulates T cell activation, which has implications in immune diseases and immunotherapy.